Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stake Increased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. increased its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 63.9% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 13,676 shares of the company’s stock after purchasing an additional 5,333 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Zentalis Pharmaceuticals were worth $50,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC grew its stake in Zentalis Pharmaceuticals by 44.3% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 67,893 shares of the company’s stock valued at $250,000 after acquiring an additional 20,848 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of Zentalis Pharmaceuticals by 195.3% during the third quarter. Exchange Traded Concepts LLC now owns 45,506 shares of the company’s stock worth $167,000 after purchasing an additional 30,098 shares during the period. SG Americas Securities LLC grew its position in Zentalis Pharmaceuticals by 84.8% during the third quarter. SG Americas Securities LLC now owns 26,149 shares of the company’s stock valued at $96,000 after purchasing an additional 11,997 shares in the last quarter. Algert Global LLC acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $78,000. Finally, Decheng Capital LLC lifted its position in Zentalis Pharmaceuticals by 46.2% in the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock worth $12,558,000 after buying an additional 970,859 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ZNTL. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, August 12th. Oppenheimer restated an “outperform” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Finally, Wedbush raised Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target for the company in a research note on Monday, August 12th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $10.78.

Zentalis Pharmaceuticals Stock Performance

ZNTL opened at $2.73 on Friday. The firm has a market cap of $194.12 million, a P/E ratio of -1.00 and a beta of 1.70. The business has a 50 day moving average price of $3.30 and a 200 day moving average price of $6.11. Zentalis Pharmaceuticals, Inc. has a twelve month low of $2.66 and a twelve month high of $18.24.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Friday, August 9th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.40). During the same period last year, the company earned ($1.85) EPS. As a group, analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -3.02 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.